Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CESAR MORAN and IGNACIO IVAN WISTUBA.
Connection Strength

4.060
  1. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1. Pathol Res Pract. 2020 Dec; 216(12):153267.
    View in: PubMed
    Score: 0.197
  2. Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Appl Immunohistochem Mol Morphol. 2019 02; 27(2):125-133.
    View in: PubMed
    Score: 0.174
  3. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017 06; 30(6):826-833.
    View in: PubMed
    Score: 0.153
  4. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases. Hum Pathol. 2017 01; 59:1-9.
    View in: PubMed
    Score: 0.147
  5. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Hum Pathol. 2015 Mar; 46(3):376-83.
    View in: PubMed
    Score: 0.130
  6. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol. 2014 Dec; 45(12):2463-70.
    View in: PubMed
    Score: 0.128
  7. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.
    View in: PubMed
    Score: 0.124
  8. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst. 2014 Mar; 106(3):dju004.
    View in: PubMed
    Score: 0.124
  9. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
    View in: PubMed
    Score: 0.124
  10. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65.
    View in: PubMed
    Score: 0.120
  11. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013 Nov 15; 19(22):6261-71.
    View in: PubMed
    Score: 0.120
  12. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. Mod Pathol. 2013 Dec; 26(12):1554-60.
    View in: PubMed
    Score: 0.118
  13. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1747-1754.
    View in: PubMed
    Score: 0.114
  14. Molecular aspects of thymic carcinoma. Lung Cancer. 2012 Nov; 78(2):127-32.
    View in: PubMed
    Score: 0.111
  15. Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung. Pathol Res Pract. 2012 Aug 15; 208(8):470-4.
    View in: PubMed
    Score: 0.110
  16. HER family receptor and ligand status in thymic carcinoma. Lung Cancer. 2012 Sep; 77(3):515-21.
    View in: PubMed
    Score: 0.110
  17. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012 Mar; 137(3):444-50.
    View in: PubMed
    Score: 0.108
  18. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99.
    View in: PubMed
    Score: 0.105
  19. Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung. Histopathology. 2011 Sep; 59(3):526-36.
    View in: PubMed
    Score: 0.104
  20. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol. 2011 Aug; 136(2):252-9.
    View in: PubMed
    Score: 0.104
  21. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res. 2011 Sep 01; 17(17):5705-14.
    View in: PubMed
    Score: 0.103
  22. Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases. Hum Pathol. 2011 Apr; 42(4):578-85.
    View in: PubMed
    Score: 0.100
  23. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr 15; 17(8):2434-43.
    View in: PubMed
    Score: 0.100
  24. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology. 2011 Jan; 58(2):276-85.
    View in: PubMed
    Score: 0.099
  25. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010 Jul 15; 16(14):3743-53.
    View in: PubMed
    Score: 0.096
  26. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011 Jan; 71(1):34-41.
    View in: PubMed
    Score: 0.095
  27. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010 Feb 09; 5(2):e9112.
    View in: PubMed
    Score: 0.093
  28. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol. 2010 Jan; 133(1):133-40.
    View in: PubMed
    Score: 0.093
  29. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68.
    View in: PubMed
    Score: 0.091
  30. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009 May; 22(5):668-78.
    View in: PubMed
    Score: 0.088
  31. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila). 2008 Aug; 1(3):192-200.
    View in: PubMed
    Score: 0.084
  32. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Jan 01; 14(1):41-7.
    View in: PubMed
    Score: 0.081
  33. Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study. Chest. 2020 10; 158(4):1723-1733.
    View in: PubMed
    Score: 0.048
  34. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Ann Thorac Surg. 2020 10; 110(4):1131-1138.
    View in: PubMed
    Score: 0.048
  35. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
    View in: PubMed
    Score: 0.047
  36. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
    View in: PubMed
    Score: 0.047
  37. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
    View in: PubMed
    Score: 0.047
  38. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol. 2018 06; 31(6):947-955.
    View in: PubMed
    Score: 0.041
  39. Pleuropulmonary Meningothelial Proliferations: Evidence for a Common Histogenesis. Am J Surg Pathol. 2015 Dec; 39(12):1673-8.
    View in: PubMed
    Score: 0.035
  40. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Res. 2015 May 15; 75(10):2029-38.
    View in: PubMed
    Score: 0.033
  41. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Hum Pathol. 2015 Jun; 46(6):836-42.
    View in: PubMed
    Score: 0.033
  42. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.